Annexon to Participate in Upcoming September Investor Conferences
Fireside chats with CEO Douglas Love and live/archived webcasts for the Sept. 9–15 events will be on Annexon’s investor site.
Rhea-AI Summary
Annexon (ANNX) will participate in three September 2026 healthcare investor conferences, featuring fireside chats with president and CEO Douglas Love.
Events include Wells Fargo on September 9 at 8:45 a.m. ET in Boston, Cantor on September 10 at 1:35 p.m. ET in New York, and H.C. Wainwright on September 15 at 1:00 p.m. ET in New York. Live and archived webcasts will be available on the company’s investor website.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 17 | Employee option grants | Neutral | +2.9% | Inducement options covering 287,500 shares were granted to three new employees. |
| Aug 12 | Second-quarter earnings | Neutral | +0.0% | Quarterly results included a $55.3 million net loss and financing updates. |
| Aug 12 | Phase 3 trial update | Neutral | +0.0% | ARCHER II added a Month 24 dual primary endpoint and extension study. |
| Aug 10 | Board appointment | Neutral | -1.0% | Mark Blumenkranz joined the board as Muneer Satter resigned immediately. |
| Aug 06 | Clinical data announcement | Positive | +4.3% | Early FORWARD data showed rapid improvement in all ten treated patients. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Historical reactions were mixed: the August 6 clinical-data announcement aligned with a gain, while the board announcement diverged with a decline.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BRISBANE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that Douglas Love, Esq., president & chief executive officer, will participate in fireside chats during the following September investor conferences:
- Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026, at 8:45 a.m. ET in Boston, MA; and,
- Cantor Global Healthcare Conference on Thursday, September 10, 2026, at 1:35 p.m. ET in New York, NY; and,
- H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026, at 1:00 p.m. ET in New York, NY.
Live webcasts of the presentations can be accessed under the ‘Events & Presentations’ section on the Investors page at annexonbio.com. Replays of the webcasts will be archived on the Annexon website for 30 days following the presentations.
About Annexon
Annexon Biosciences (Nasdaq: ANNX) is advancing the next generation platform of targeted immunotherapies for nearly 10 million people worldwide living with serious neuroinflammatory diseases. Our founding scientific approach focuses on C1q, the initiating molecule of a potent inflammatory pathway that when misdirected can lead to tissue damage and loss of function in a host of diseases. Our targeted therapies are designed to stop classical complement-driven neuroinflammation at its source to provide meaningful functional benefit and alter the course of disease. Annexon’s mission is to deliver game-changing therapies to patients so that they can live their best lives. To learn more visit annexonbio.com.
Investor Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
Media Contact:
Beth Keshishian
917-912-7195
beth@bethkeshishian.com
